3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
6
Breast Neoplasms
6
Vomiting
2
Solid Tumors
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Diabetes Mellitus
2
Weight Gain
1
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Skin Toxicity
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Premature Birth
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pre-Eclampsia
1
Polycythemia Vera
1
Parathyroid Neoplasms
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Nausea
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Interventions
Sunitinib
86
Sorafenib
60
Everolimus
47
pazopanib
46
Bevacizumab
46
Nivolumab
44
pembrolizumab
37
aldesleukin
29
Interferon-alpha
26
Axitinib
24
temsirolimus
23
cabozantinib
20
Interleukin-2
19
Ipilimumab
16
Interferon alpha-2
15
Cyclophosphamide
15
fludarabine phosphate
14
Gemcitabine
14
Peripheral Blood Stem Cell Transplantation
11
Sirolimus
10
Paclitaxel
10
Erlotinib Hydrochloride
10
avelumab
8
Radiosurgery
8
Docetaxel
8
Cyclosporine
8
Capecitabine
8
tremelimumab
7
lenvatinib
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Renal Cell
×
Tablets
×
Clear all
NCT01865747
2021-04-27
METEOR
Exelixis
Phase 3
Completed
658 enrolled
15 charts